The move is set to increase rates of early diagnosis. Credit: Darko Stojanovic via Pixabay.

Life Molecular Imaging (LMI) and its partner CMI have received approval for the reimbursement of the amyloid positron emission tomography (PET) diagnostic tool, Neuraceq, by governmental health insurance.

The C2 path approval from the Japanese Ministry of Health, Labor, and Welfare marks Neuraceq the first amyloid PET diagnostic tool currently reimbursed in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Neuraceq radioactive diagnostic agent is indicated for PET imaging of the brain. It is used to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment being assessed to treat Alzheimer’s disease.

LMI said the reimbursement will allow Japanese physicians to use the diagnostic tool to accurately assess their patients with cognitive decline.

By assessing the density of amyloid plaques, earlier diagnosis can be improved and further guide therapy and patient management.

See Also:

LMI managing director Dr Ludger Dinkelborg said: “Achieving reimbursement for amyloid PET using Neuraceq in Japan is an important milestone. We are pleased that our amyloid PET tracer, a very important and reliable diagnostic imaging agent, is now available for more Japanese patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LMI Americas and APAC COO Colleen Ruby added: “We will continue to work with our partner CMI in Japan to improve the diagnosis of patients being evaluated for mild cognitive impairment (MCI) and Alzheimer’s disease, and to make Neuraceq available to more referring physicians across the country.”

Available in Japan from the approved Synthera+ medical device, Neuraceq is accessible at Keio University Hospital, Tokyo, Koseikai Takeda Hospital, Kyoto and Uozumi Clinic, Kumamoto.